ES2873601T3 - Formulaciones de honokiol y magnolol con estabilidad incrementada y absorción mejorada y procedimientos de uso de las mismas - Google Patents

Formulaciones de honokiol y magnolol con estabilidad incrementada y absorción mejorada y procedimientos de uso de las mismas Download PDF

Info

Publication number
ES2873601T3
ES2873601T3 ES16836765T ES16836765T ES2873601T3 ES 2873601 T3 ES2873601 T3 ES 2873601T3 ES 16836765 T ES16836765 T ES 16836765T ES 16836765 T ES16836765 T ES 16836765T ES 2873601 T3 ES2873601 T3 ES 2873601T3
Authority
ES
Spain
Prior art keywords
formulation
honokiol
magnolol
vso
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16836765T
Other languages
English (en)
Spanish (es)
Inventor
Bomi P Framroze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ST IP Holding AG
Original Assignee
ST IP Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ST IP Holding AG filed Critical ST IP Holding AG
Application granted granted Critical
Publication of ES2873601T3 publication Critical patent/ES2873601T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A61K36/575—Magnolia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES16836765T 2015-08-17 2016-01-18 Formulaciones de honokiol y magnolol con estabilidad incrementada y absorción mejorada y procedimientos de uso de las mismas Active ES2873601T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2534DE2015 2015-08-17
PCT/IN2016/050021 WO2017029683A1 (en) 2015-08-17 2016-01-18 Honokiol and magnolol formulations with increased stability and improved uptake, and methods of use thereof

Publications (1)

Publication Number Publication Date
ES2873601T3 true ES2873601T3 (es) 2021-11-03

Family

ID=58051448

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16836765T Active ES2873601T3 (es) 2015-08-17 2016-01-18 Formulaciones de honokiol y magnolol con estabilidad incrementada y absorción mejorada y procedimientos de uso de las mismas

Country Status (12)

Country Link
US (1) US10328090B2 (enExample)
EP (1) EP3337487B1 (enExample)
JP (1) JP6663993B2 (enExample)
KR (1) KR20180050331A (enExample)
AU (2) AU2016308080A1 (enExample)
CA (1) CA2995834A1 (enExample)
DK (1) DK3337487T3 (enExample)
ES (1) ES2873601T3 (enExample)
HU (1) HUE054161T2 (enExample)
PL (1) PL3337487T3 (enExample)
PT (1) PT3337487T (enExample)
WO (1) WO2017029683A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019183141A1 (en) 2018-03-21 2019-09-26 Realtime Robotics, Inc. Motion planning of a robot for various environments and tasks and improved operation of same
KR20200083304A (ko) * 2018-12-28 2020-07-08 충북대학교 산학협력단 일본 목련 추출물을 유효성분으로 함유하는 불안장애의 예방 또는 치료용 약학적 조성물
WO2020154712A1 (en) * 2019-01-25 2020-07-30 Flaask, Llc Compositions and methods for improving quality of life in patients with autism spectrum disorder
CN110585140A (zh) * 2019-07-08 2019-12-20 苏州海特比奥生物技术有限公司 一种和厚朴酚纳米聚合物胶束冻干制剂及其制备方法
US12213505B2 (en) * 2021-07-05 2025-02-04 Healthy Ingredient Solutions, LLC Composition for promoting restful sleep and methods of making and using the same
WO2025136962A1 (en) * 2023-12-19 2025-06-26 Rebalance Health, Inc. Compositions for reducing hot flashes and symptoms associated with anxiety and formulations thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582735B2 (en) 2000-12-15 2003-06-24 Npi, Llc. Compositions and methods of use for extracts of magnoliaceae plants
US7632525B2 (en) 2002-06-25 2009-12-15 Wm. Wrigley Jr. Company Breath freshening and oral cleansing product with magnolia bark extract in combination with surface active agents
CN1723011A (zh) 2002-06-25 2006-01-18 Wm·雷格利Jr·公司 含有厚朴提取物的口气清新和口腔清洁产品
CN101321537A (zh) 2005-12-02 2008-12-10 Gic创新公司 含厚朴提取物的糖食组合物
RU2396941C2 (ru) 2005-12-02 2010-08-20 Джи Ай Си ИННОВАТИОНЗ КОМПАНИ Наполнители с экстрактом коры магнолии для ухода за полостью рта
RU2398593C2 (ru) 2005-12-02 2010-09-10 Джи Ай Си ИННОВАТИОНЗ КОМПАНИ Жевательные составы с экстрактом коры магнолии быстрого высвобождения
BRPI0810435A2 (pt) 2007-04-19 2014-11-25 Mary Kay Inc Composições contendo extrato de magnólia
WO2011115476A1 (en) * 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
DE102010015791A1 (de) * 2010-04-20 2011-10-20 Beiersdorf Ag Wirkstoffkombinationen aus Magnolienrindenextrakt und polyethoxylierten Verbindungen
DE102010015792A1 (de) * 2010-04-20 2011-10-20 Beiersdorf Ag Wirkstoffkombinationen aus Magnolienrindenextrakt und oberflächenaktiven Agentien
EP2611313A1 (en) * 2010-09-03 2013-07-10 N.V. Nutricia Method and preparation for the treatment or prevention of anxiety or neurogenesis
FR2970294B1 (fr) * 2011-01-11 2012-12-28 Peugeot Citroen Automobiles Sa Ligne d'echappement pour un moteur a combustion interne
IE20110008A1 (en) 2011-01-12 2012-08-01 Patrick Thomas Prendergast Compositions for alleviating:- stress, anxiety, depression and aiding with weight loss
WO2013043151A1 (en) 2011-09-19 2013-03-28 Framroze Bomi P Edible oil with a high concentration of poly-unsaturated fatty acids
CA2849294C (en) * 2011-09-20 2023-03-21 Vivaquant Llc Physiological signal denoising

Also Published As

Publication number Publication date
PT3337487T (pt) 2021-05-27
WO2017029683A1 (en) 2017-02-23
KR20180050331A (ko) 2018-05-14
US20180147220A1 (en) 2018-05-31
JP6663993B2 (ja) 2020-03-13
EP3337487B1 (en) 2021-02-24
EP3337487A4 (en) 2019-04-03
DK3337487T3 (da) 2021-05-25
JP2018528266A (ja) 2018-09-27
US10328090B2 (en) 2019-06-25
AU2016308080A1 (en) 2018-03-22
PL3337487T3 (pl) 2021-12-06
EP3337487A1 (en) 2018-06-27
AU2022201271A1 (en) 2022-03-17
CA2995834A1 (en) 2017-02-23
HUE054161T2 (hu) 2021-08-30

Similar Documents

Publication Publication Date Title
ES2873601T3 (es) Formulaciones de honokiol y magnolol con estabilidad incrementada y absorción mejorada y procedimientos de uso de las mismas
US10631556B2 (en) Method for conducing concentrated cannabis oil to be stable, emulsifiable and flavorless for use in hot beverages and resulting powderized cannabis oil
CN105962359A (zh) 一种具有辅助改善记忆功能的组合物
JP2006083151A (ja) 骨粗鬆症予防、改善用組成物
WO2010002406A1 (en) Compositions comprising rhodiola rosea and methods of use thereof
US20090175968A1 (en) Dietary compositions for promoting brain health
JP7655920B2 (ja) 認知障害の治療に使用する組成物
JPWO2020004357A1 (ja) アルツハイマー病の治療、予防又は改善用組成物、脳神経細胞死の抑制用組成物、アミロイドβペプチドで誘導されるミクログリアの活性化の抑制用組成物、及び、アミロイドβペプチドで誘導されるＰＧＥ２、ＴＮＦ−α又はＩＬ−１β産生の抑制用組成物
KR20030022366A (ko) 주의 결함 다동성 장해 개선용 조성물
JP5403320B2 (ja) 天然抽出物より得られた脱顆粒抑制剤、β−ヘキソサミニダーゼ遊離抑制剤、抗アレルギー剤および抗炎症剤
EP2089505A1 (en) Reduced-hangover alcoholic beverage
EP2712619B1 (en) Composition for preventing or treating dementia comprising extracts of monsonia species
JP6510017B1 (ja) 神経細胞死抑制剤及び神経細胞死抑制用食品組成物
KR20140101119A (ko) 베툴린 또는 이의 약제학적으로 허용되는 염을 포함하는 학습과 기억력 또는 인지기능 개선용 조성물
JP6061754B2 (ja) ノコギリヤシエキス配合製剤
JP2020189802A (ja) サーチュイン１活性化剤及びサーチュイン１活性化用皮膚化粧料
US20230219015A1 (en) Extraction method and mixture of substances
CN119969583A (zh) 一种缓解抑郁的组合物及其制备方法和应用
BR102021024155A2 (pt) Uso de uma solução/emulsão a partir de ziziphus cotinifolia reissek no tratamento dos transtornos da ansiedade
US20110038943A1 (en) Milkweed seed oil administered to animals
JP2007186431A (ja) 抗酸化組成物及び脳神経細胞保護用医薬組成物、抗酸化剤及び脳神経細胞保護剤、並びにそれらの使用方法
Kaur et al. Mahua's Adaptogenic Nature: Benefits and Mechanisms
CN103479807B (zh) 一种用于脑保护的组合物及其制备方法和用途
KR20150016625A (ko) 베툴린 또는 이의 약제학적으로 허용되는 염을 포함하는 학습과 기억력 또는 인지기능 개선용 조성물
JP2018024654A (ja) プロポリスのミセル化抽出物を有効成分とする認知機能改善剤